Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.646,91
-0,38%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ultragenyx Pharmaceutical Inc (RARE) Ultragenyx Pharmaceutical Inc (RARE) Notizie

Ultragenyx Pharmaceutical Inc

RARE
42,75
-0,45 (-1,04%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202422:00GLOBEUltragenyx Reports First Quarter 2024 Financial Results and..
30/4/202422:00GLOBEUltragenyx Issues 2023 Corporate Responsibility Report,..
30/4/202414:00GLOBEUltragenyx Announces Completion of Enrollment in Phase 3..
25/4/202422:30GLOBEUltragenyx to Host Conference Call for First Quarter 2024..
19/4/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
15/4/202413:00GLOBEUltragenyx Announces Positive Interim Phase 1/2 Data in..
12/4/202422:22GLOBEUltragenyx Announces Update to Conference Call Timing to..
12/4/202414:00GLOBEUltragenyx Announces Upcoming Data Presentations at American..
22/3/202421:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
06/3/202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:30GLOBEUltragenyx to Participate at Investor Conferences in March
23/2/202422:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
21/2/202423:03EDGAR2Form S-3ASR - Automatic shelf registration statement of..
15/2/202422:04EDGAR2Form 8-K - Current report
15/2/202422:01GLOBEUltragenyx Reports Fourth Quarter and Full Year 2023..
08/2/202422:00GLOBEUltragenyx to Host Conference Call for Fourth Quarter and..
06/2/202414:00GLOBEUltragenyx Announces Data Demonstrating Treatment with UX111..
05/2/202422:05GLOBEUltragenyx Receives PRIME Designation from European..
25/1/202422:05GLOBEUltragenyx Announces Completion of Dosing Across Stage 1..
19/1/202422:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
08/1/202413:00GLOBEMereo BioPharma Provides Update on Pipeline Progress and..
08/1/202412:03EDGAR2Form 8-K - Current report
07/1/202417:00GLOBEUltragenyx Reports Preliminary 2023 Revenue; Guidance for..
04/1/202414:00GLOBEUltragenyx Receives Positive Recommendation from NICE in the..
03/1/202414:00GLOBEUltragenyx Announces Completion of Enrollment in Global..
02/1/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:05GLOBEUltragenyx to Present at the 42nd Annual J.P. Morgan..
21/12/202323:45DJNUltragenyx to Pay $6 Million to Settle Alleged False..
21/12/202322:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
21/12/202322:02EDGAR2Form 8-K - Current report
18/12/202314:00GLOBEUltragenyx Receives European Commission Decision for..
20/11/202322:30GLOBEUltragenyx to Participate at Investor Conferences in..
17/11/202322:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
07/11/202323:00GLOBEUltragenyx to Participate in the Jefferies London Healthcare..
02/11/202321:17EDGAR2Form 8-K - Current report
02/11/202321:05GLOBEUltragenyx Reports Third Quarter 2023 Financial Results and..
26/10/202322:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2023..
23/10/202322:01GLOBEUltragenyx Announces Closing of Public Offering of Common..
23/10/202312:31EDGAR2Form 8-K - Current report
20/10/202322:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
20/10/202312:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/10/202303:16GLOBEUltragenyx Announces Pricing of Public Offering of Common..
17/10/202322:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/10/202322:02GLOBEUltragenyx Announces Proposed Public Offering of Common..
Apertura: 44,88 Min: 42,675 Max: 46,005
Chiusura: 43,20

La tua Cronologia

NASDAQ
RARE
Ultragenyx Pharmaceutical
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network